Table 4.
Additional treatments.
| (a) Numbers of patients and cycles of chemotherapy | |||||
|---|---|---|---|---|---|
| Group | N | Treated | Cycles | Median | Total cycles |
| Control | 47 | 23 (49%) | 1–6 | 3 | 68 |
| Metastasectomy | 46 | 19 (41%) | 2–7 | 3 | 60 |
| (b) Timing from randomisation in months | ||||||
|---|---|---|---|---|---|---|
| Group | N | < 6* | 6–12 | Earliest | Median | IQR |
| Control | 47 | 9 | 3 | 0.4 | 11.6 | 2.3–16.4 |
| Metastasectomy | 46 | 6 | 7 | 1.0 | 7.8 | 5.4–14.1 |
| (c) Radiotherapy and IGTA in months | |||||
|---|---|---|---|---|---|
| Radiotherapy | N | < 6 | 6–12 | > 12 | Total |
| Control | 47 | 0 | 1 | 3 | 4 |
| Metastasectomy | 46 | 0 | 1 | 4 | 5 |
| IGTA | N | < 6 | 6–9 | 9–12 | > 12 | Total |
|---|---|---|---|---|---|---|
| Control | 47 | 0 | 1 | 1 | 1 | 3 |
| Metastasectomy | 46 | 0 | 1 | 1 | 0 | 2 |
*
Any differences may in part reflect considerations of fitness for chemotherapy in the post‐operative period.